A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NON RANDOMIZED · SINGLE GROUP · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 13
- Population
- ALL · 12 Years
- Duration
- 2010-10-01 to 2013-02-01
- Intervention
- VX-770; Placebo
- Comparator
- Not reported
- Outcomes measured
- Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging…; Part B: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging…; Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs — Part A: Day 1…; Part A: Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Day 43 — Part A: Basel…; Part A: Absolute Change From Baseline in Sweat Chloride at Day 43 — Part A: Baseline (pre-dose Day 15), Day 43; Part A: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score At Day…; Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs — Part B: Day 1…; Part B: Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 48 — Part B: Base…; Part B: Absolute Change From Baseline in Sweat Chloride at Week 48 — Part B: Baseline (Day -1), Week 48; Part B: Absolute Change From Baseline in in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score At W…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Extracellular matrix ageing · 100%Title contains controlled term: fibrosis. Abstract contains controlled term: fibrosis. Source terminology contains: fibrosis. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.